[go: up one dir, main page]

CY1113199T1 - Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης - Google Patents

Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης

Info

Publication number
CY1113199T1
CY1113199T1 CY20121100952T CY121100952T CY1113199T1 CY 1113199 T1 CY1113199 T1 CY 1113199T1 CY 20121100952 T CY20121100952 T CY 20121100952T CY 121100952 T CY121100952 T CY 121100952T CY 1113199 T1 CY1113199 T1 CY 1113199T1
Authority
CY
Cyprus
Prior art keywords
compositions
glucoseremproduction
stabilized
making
methods
Prior art date
Application number
CY20121100952T
Other languages
English (en)
Inventor
Gaozhong Zhu
Kris Lowe
Zahra Shahrokh
Vinh Nguyen
Original Assignee
Shire Human Genetic Therapies, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies, Inc filed Critical Shire Human Genetic Therapies, Inc
Publication of CY1113199T1 publication Critical patent/CY1113199T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/04—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Περιγράφονται συνθέσεις πρωτεϊνών που έχουν ελεύθερες θειόλες και μέθοδοι κατασκευής και χρήσης τέτοιων συνθέσεων.
CY20121100952T 2006-02-07 2012-10-12 Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης CY1113199T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77155506P 2006-02-07 2006-02-07
EP07763599A EP1986612B1 (en) 2006-02-07 2007-02-06 Stabilized composition of glucocerebrosidase

Publications (1)

Publication Number Publication Date
CY1113199T1 true CY1113199T1 (el) 2016-04-13

Family

ID=38252288

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100952T CY1113199T1 (el) 2006-02-07 2012-10-12 Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης

Country Status (16)

Country Link
US (5) US7833766B2 (el)
EP (2) EP2361613B1 (el)
JP (8) JP5364382B2 (el)
AR (3) AR059347A1 (el)
AU (1) AU2007212021B2 (el)
CA (1) CA2641588C (el)
CY (1) CY1113199T1 (el)
DK (1) DK1986612T3 (el)
ES (1) ES2391657T3 (el)
HR (1) HRP20120994T1 (el)
PL (1) PL1986612T3 (el)
PT (1) PT1986612E (el)
RS (1) RS52459B (el)
SI (1) SI1986612T1 (el)
TW (1) TWI415630B (el)
WO (1) WO2007092829A2 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
EP2361613B1 (en) * 2006-02-07 2020-08-12 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
EP2183007A1 (en) * 2007-08-27 2010-05-12 Ablynx N.V. Needle-free delivery device for therapeutic proteins based on single antigen-binding domains such as nanobodies®
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
MX2010007150A (es) 2007-12-28 2010-09-03 Baxter Int Formulaciones del factor de von-willebrand recombinante.
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
AU2009205995B2 (en) * 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
EP2113564A1 (en) * 2008-05-01 2009-11-04 Arecor Limited Protein formulation
WO2010021752A1 (en) 2008-08-21 2010-02-25 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
US9017667B2 (en) * 2008-10-10 2015-04-28 Alvine Pharmaceuticals, Inc. Dosage forms that facilitate rapid activation of barley protease zymogen
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
EP2427211A4 (en) * 2009-05-04 2013-05-01 Abbott Biotech Ltd STABLE FORMULATIONS WITH HIGH PROTEIN CONCENTRATION OF ANTI-TNF-ALPHA HUMAN ANTIBODIES
PL3354277T3 (pl) * 2009-07-28 2021-12-13 Takeda Pharmaceutical Company Limited Kompozycje i sposoby leczenia choroby gauchera
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
EP2555793B1 (en) * 2010-04-08 2015-07-08 Baxter International Inc. Methods for modeling protein stability
WO2012065072A2 (en) 2010-11-11 2012-05-18 Abbott Biotechnology Ltd. IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法
CN104519905A (zh) 2012-03-02 2015-04-15 夏尔人类遗传性治疗公司 用于治疗iii型戈谢病的组合物和方法
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
WO2016020210A1 (en) 2014-08-04 2016-02-11 Csl Behring Gmbh Csl behring gmbh
US9575064B2 (en) * 2014-09-02 2017-02-21 Perkinelmer Health Sciences, Inc. Methods relating to testing for lysosomal storage disorders
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
EP3994162A1 (en) 2019-07-04 2022-05-11 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP4041881A4 (en) * 2019-10-09 2023-11-08 Phoenix Eagle Company Pty Ltd ENHANCEMENT AND STABILIZATION OF THE PROTEOLYTIC ACTIVITY OF PROTEASES
JP2022551306A (ja) * 2019-10-09 2022-12-08 フェニックス イーグル カンパニー ピーティーワイ リミテッド プロテアーゼのタンパク質分解活性の増強及び安定化
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
KR20240163906A (ko) * 2023-05-11 2024-11-19 씨제이제일제당 (주) 포스포리파아제 안정화용 조성물 및 이를 이용한 포스포리파아제 안정화 방법

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910822A (en) 1974-03-14 1975-10-07 Us Health Isolation of glucocerebrosidase from human placental tissue
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4925796A (en) 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5272066A (en) 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP0393143A4 (en) 1987-12-23 1991-09-11 Us Commerce Cloned dna for synthesizing unique glucocerebrosidase
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
JPH03503721A (ja) 1988-12-23 1991-08-22 ジェンザイム　コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
JP2893481B2 (ja) 1988-12-23 1999-05-24 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
US20020168750A1 (en) 1988-12-23 2002-11-14 James Rasmussen Enzymatically active recombinant glucocerebrosidase
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2099876C (en) 1991-01-21 2002-03-26 Michael L. Hayes Production of enzymatically active glucocerebrosidase from recombinant cells
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2150956A1 (en) * 1992-12-10 1994-06-23 Robert G. L. Shorr Glycolipid enzyme-polymer conjugates
WO1994014837A1 (en) 1992-12-21 1994-07-07 Enzon, Inc. Purification of proteinaceous material
EP0675204B1 (en) 1994-03-30 2001-05-30 Takara Shuzo Co. Ltd. Transglycosylating process for producing carbohydrates or glycoconjugates
JP3002113B2 (ja) 1994-03-30 2000-01-24 寳酒造株式会社 糖質又は複合糖質の製造方法
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
AU693329B2 (en) 1995-04-13 1998-06-25 Corning Incorporated Dispersion managed optical waveguide
MX9800684A (es) * 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
ATE426031T1 (de) 1995-09-14 2009-04-15 Virginia Tech Intell Prop Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
JP2002504083A (ja) * 1996-03-05 2002-02-05 オーケスト インコーポレイテッド ヒアルロン酸および増殖因子による骨の増殖を促進する方法
DE69735669T2 (de) 1996-07-15 2007-03-29 Macrozyme Dnm B.V. Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
RU2179034C2 (ru) 1996-09-13 2002-02-10 Транскариотик Терапиз, Инк. ЛЕЧЕНИЕ В СЛУЧАЕ ДЕФИЦИТА α-ГАЛАКТОЗИДАЗЫ А
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JPH10273500A (ja) 1997-03-03 1998-10-13 Noguchi Inst 複合糖ペプチド及びその製造法
JPH10306099A (ja) 1997-03-04 1998-11-17 Noguchi Inst 新規複合糖ペプチドおよびその製法
TW542721B (en) * 1997-08-06 2003-07-21 Melaleuca Inc Dietary supplements containing natural ingredients
CA2299271C (en) * 1997-08-07 2009-02-03 University Of Utah Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof
US5939279A (en) 1997-09-18 1999-08-17 The Board Of Trustees Of The University Of Arkansas Inhibition of bacterial binding by high-mannose oligosaccharides
KR20010033484A (ko) * 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2 제제
GB9802249D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
GB9807464D0 (en) 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
EP0976838A1 (en) 1998-05-06 2000-02-02 Rhone-Poulenc Nutrition Animale Enzymes mixture
JPH11318441A (ja) 1998-05-14 1999-11-24 Nagase & Co Ltd 超耐熱耐酸性アミロプルラナーゼ
KR19990086271A (ko) 1998-05-27 1999-12-15 손경식 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
AU4045599A (en) 1998-06-05 1999-12-30 Aventis Pharma S.A. Polypeptides with beta-secretase type activity
US6998267B1 (en) 1998-12-09 2006-02-14 The Dow Chemical Company Method for manufacturing glycoproteins having human-type glycosylation
US6406455B1 (en) 1998-12-18 2002-06-18 Biovalve Technologies, Inc. Injection devices
GB9909066D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
EP1189599A2 (en) 1999-06-11 2002-03-27 Eli Lilly And Company Pharmaceutical materials and methods for their preparation and use
JP2003505430A (ja) * 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
EP1246915A2 (en) 1999-12-30 2002-10-09 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
WO2001077307A2 (en) 2000-04-06 2001-10-18 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
WO2002055128A2 (en) 2000-11-30 2002-07-18 Biovalve Technologies Inc Fluid delivery and measurement systems and methods
KR20030067755A (ko) 2001-01-18 2003-08-14 메르크 파텐트 게엠베하 글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질
CN1156702C (zh) 2001-07-11 2004-07-07 上海晶泰生物技术有限公司 采用标记链霉亲和素-生物素技术的蛋白质芯片
US20030133924A1 (en) 2001-12-21 2003-07-17 Novazyme Pharmaceuticals, Inc. Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
AU2003251906B2 (en) * 2002-07-12 2008-12-04 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US7194924B2 (en) * 2002-07-31 2007-03-27 Lockheed Martin Corporation System and method for biohazard detection using compression
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
SI2444102T1 (sl) * 2003-01-31 2015-08-31 Mount Sinai School Of Medicine Of New York University Kombinirana terapija za zdravljenje motenj pomanjkanja proteina
US20050265988A1 (en) 2004-03-18 2005-12-01 Byung-Kwon Choi Glycosylated glucocerebrosidase expression in fungal hosts
TW200606080A (en) * 2004-05-26 2006-02-16 Bristol Myers Squibb Co Container
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
US7385028B2 (en) * 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
EP2361613B1 (en) 2006-02-07 2020-08-12 Shire Human Genetic Therapies, Inc. Stabilized compositions of proteins having a free thiol moiety
JP2009529885A (ja) 2006-03-17 2009-08-27 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム酵素に対する抗体の検出のためのアッセイ
US8905801B1 (en) 2007-12-31 2014-12-09 Brp Us Inc. Marine outboard motor
PL3354277T3 (pl) 2009-07-28 2021-12-13 Takeda Pharmaceutical Company Limited Kompozycje i sposoby leczenia choroby gauchera
US20120328589A1 (en) 2010-03-02 2012-12-27 Ilya Ruderfer Glucocerebrosidase multimers and uses thereof
JP5383591B2 (ja) 2010-05-24 2014-01-08 日立建機株式会社 建設機械の油圧駆動装置
EP2595651B1 (en) 2010-07-19 2017-03-29 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
JP5806015B2 (ja) 2011-06-30 2015-11-10 矢崎総業株式会社 電気接続箱

Also Published As

Publication number Publication date
JP2016196512A (ja) 2016-11-24
US9694057B2 (en) 2017-07-04
JP2015164960A (ja) 2015-09-17
JP2013010785A (ja) 2013-01-17
EP1986612B1 (en) 2012-09-12
JP5795295B2 (ja) 2015-10-14
AR059347A1 (es) 2008-03-26
CA2641588C (en) 2014-06-17
TW200800296A (en) 2008-01-01
HRP20120994T1 (hr) 2012-12-31
JP6894493B2 (ja) 2021-06-30
AR078885A2 (es) 2011-12-07
DK1986612T3 (da) 2012-10-29
US20180104314A1 (en) 2018-04-19
US7833766B2 (en) 2010-11-16
JP5364382B2 (ja) 2013-12-11
US20110091414A1 (en) 2011-04-21
JP2018035183A (ja) 2018-03-08
ES2391657T3 (es) 2012-11-28
JP2019116509A (ja) 2019-07-18
AU2007212021A1 (en) 2007-08-16
US20150283216A1 (en) 2015-10-08
US20140219987A1 (en) 2014-08-07
EP1986612A2 (en) 2008-11-05
TWI415630B (zh) 2013-11-21
JP2009526080A (ja) 2009-07-16
WO2007092829A2 (en) 2007-08-16
US8673298B2 (en) 2014-03-18
JP2021066752A (ja) 2021-04-30
EP2361613B1 (en) 2020-08-12
RS52459B (en) 2013-02-28
AR107785A2 (es) 2018-06-06
AU2007212021B2 (en) 2013-06-06
CA2641588A1 (en) 2007-08-16
PL1986612T3 (pl) 2013-02-28
JP6175102B2 (ja) 2017-08-02
US9072785B2 (en) 2015-07-07
SI1986612T1 (sl) 2013-01-31
PT1986612E (pt) 2012-11-06
US20070197439A1 (en) 2007-08-23
WO2007092829A3 (en) 2007-10-18
EP2361613A1 (en) 2011-08-31
JP2020041000A (ja) 2020-03-19

Similar Documents

Publication Publication Date Title
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CY2018013I1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DE602007012559D1 (de) H die schleimhaut
CY1114926T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CY2016029I2 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
CY2015043I1 (el) Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων
MX358705B (es) Agentes de union de esclerostina.
NO20076003L (no) TGF-beta 1 spesifikke antistoffer
SG170750A1 (en) Stabilized polypeptide compositions
DK2074143T3 (da) Ændrede antistoffer
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
BRPI0606687A2 (pt) composições nutracêuticas
ECSP088759A (es) Composiciones farmacéuticas
MEP35408A (en) Tweak binding antibodies
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
MY148635A (en) Anti-tat226 antibodies and immunoconjugates
UY3723Q (es) Aerosol
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EP2068339A4 (en) Electron source
CY1113309T1 (el) Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
EA200702193A1 (ru) Гликозилирование белков
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same